Carolyn S.P. Lam

May 27, 2024 | onlinelibrary.wiley.com | Maria A. Pabon |Muthiah Vaduganathan |Carolyn S.P. Lam

Corresponding Author Maria A. Pabon Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Corresponding author. Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA. Tel: +1 857 307-1960, Fax: +1 857 307-1944, Email: [email protected] for more papers by this author

May 23, 2024 | onlinelibrary.wiley.com | Carolyn S.P. Lam

Mineralocorticoid receptor antagonists are a mainstay of treatment in patients with heart failure (HF) with reduced ejection fraction, but are underused in those who also have chronic kidney disease ...

May 14, 2024 | onlinelibrary.wiley.com | Muthiah Vaduganathan |Brian Claggett |Carolyn S.P. Lam |Bertram Pitt

Introduction Activation of the mineralocorticoid receptor (MR) by aldosterone has long been recognized as a central driver of heart failure (HF) pathogenesis.1 Mechanistically, ligand binding to the nuclear MR triggers a diverse signalling cascade contributing to excess salt and water retention, systemic hypertension, endothelial dysfunction, and pathological fibrosis, hypertrophy, and inflammation of the end organs, including the heart and kidneys.2 These core mechanisms of disease...

Mar 1, 2024 | jacc.org | Peder Myhre |Carolyn S.P. Lam

References1. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". N Engl J Med . 2014;371:11: 993-1004. 2. "Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure". N Engl J Med . 2018;380:6: 539-548. 3. "Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines–Heart Failure (GWTG-HF)". J Am Coll Cardiol HF . 2017;5:4: 305-309. 4.

Feb 1, 2024 | jacc.org | Xiaowen Wang |Carolyn S.P. Lam |Muthiah Vaduganathan |Toru Kondo

IntroductionAsia comprises 60% of the world's population and is both ethnically and socioeconomically diverse. With a rapidly aging population, urbanization, and increased prevalence of comorbidities such as diabetes, obesity, and hypertension, heart failure (HF) has become an urgent public health concern in this region.1Epidemiological data suggest that many Asian countries have worse HF outcomes compared with Western countries, but with significant variation among nations.